Literature DB >> 11325068

Lack of association between genetic polymorphism of CYP11B2 and hypertension in Japanese: the Suita Study.

Y Tsujita1, N Iwai, T Katsuya, J Higaki, T Ogihara, S Tamaki, M Kinoshita, T Mannami, J Ogata, S Baba.   

Abstract

Aldosterone synthase (CYP11B2) is a key enzyme in the biosynthesis of aldosterone. Recently, a polymorphism in the 5'-flanking region of the CYP11B2 gene [T(-344)C] has been reported to be associated with blood pressure and plasma aldosterone levels. We investigated the association between this polymorphism and hypertension in a large population-based sample of 4,000 Japanese. The genotype distribution in hypertensive subjects (n=1,535) was compared to that in normotensive subjects (n=2,514). In subjects not receiving antihypertensive medication, the influence of the genotype on blood pressure values adjusted for clinical covariates was analyzed. All analyses were performed separately for men and women. The genotype distribution did not differ between hypertensive and normotensive subjects in either men (frequency of C allele: 30.3% vs. 31.4%, p=0.48) or women (31.5% vs. 31.7%, p=0.93). There were no significant differences in systolic blood pressure, diastolic blood pressure, or pulse pressure among the three genotypes in either men or women who had not received hypertensive medication. Our data suggest that the T(-344)C polymorphism of CYP11B2 is unlikely to influence blood pressure status in the Japanese population.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11325068     DOI: 10.1291/hypres.24.105

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  8 in total

1.  Interaction between the C(-344)T polymorphism of CYP11B2 and alcohol consumption on the risk of essential hypertension in a Chinese Mongolian population.

Authors:  Xing-Qiang Pan; Yong-Hong Zhang; Yong-Yue Liu; Wei-Jun Tong
Journal:  Eur J Epidemiol       Date:  2010-09-29       Impact factor: 8.082

2.  Associations between human aldosterone synthase CYP11B2 (-344T/C) gene polymorphism and antihypertensive response to valsartan in Chinese patients with essential hypertension.

Authors:  Xu Ji; Hua Qi; Dong-Bao Li; Rong-Kun Liu; Yang Zheng; Hai-Ling Chen; Jin-Cheng Guo
Journal:  Int J Clin Exp Med       Date:  2015-01-15

Review 3.  Aldosterone and arterial hypertension.

Authors:  Andreas Tomaschitz; Stefan Pilz; Eberhard Ritz; Barbara Obermayer-Pietsch; Thomas R Pieber
Journal:  Nat Rev Endocrinol       Date:  2009-12-22       Impact factor: 43.330

Review 4.  Genetics of stress response and stress-related disorders.

Authors:  Marcus Ising; Florian Holsboer
Journal:  Dialogues Clin Neurosci       Date:  2006       Impact factor: 5.986

5.  Effect of ACE, ACE2 and CYP11B2 gene polymorphisms and noise on essential hypertension among steelworkers in China: a case-control study.

Authors:  Xiaohong Zhang; Ying Wang; Yao Zheng; Juxiang Yuan; Junwang Tong; Jingya Xu; Qinglin Li; Peishuai Li; Shoufang Jiang; Zhaoyang Wang; Feng Chai; Xiangwen Li
Journal:  BMC Med Genomics       Date:  2022-02-08       Impact factor: 3.063

Review 6.  Hypertension in Asian/Pacific Island Americans.

Authors:  Ralph E Watson; Rudruidee Karnchanasorn; Ved V Gossain
Journal:  J Clin Hypertens (Greenwich)       Date:  2009-03       Impact factor: 3.738

7.  Genetic polymorphisms and the risk of accelerated renal function decline in women.

Authors:  Cynthia Cooper Worobey; Naomi D L Fisher; David Cox; John P Forman; Gary C Curhan
Journal:  PLoS One       Date:  2009-03-10       Impact factor: 3.240

8.  Genetic variant of the renin-angiotensin system and prevalence of type 2 diabetes mellitus: a modest but significant effect of aldosterone synthase.

Authors:  Mai Ichikawa; Tadashi Konoshita; Takahiro Nakaya; Katsushi Yamamoto; Mika Yamada; Satsuki Sato; Michiko Imagawa; Yasukazu Makino; Miki Fujii; Yasuo Zenimaru; Kenichiro Arakawa; Jinya Suzuki; Tamotsu Ishizuka; Hiroyuki Nakamura
Journal:  Acta Diabetol       Date:  2014-02-19       Impact factor: 4.280

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.